All News

#ACR22 Plenary II. Abstr#1113 Promising news in #Sjogren. Phase 2 RCT showed oral BTK-i Remibrutinib improved ESSDAI score vs Placebo (delta -2.8) & salivary flow at Wks 24. ESSPRI unchanged. No major safety concern. Look forward to Phase 3 results soon @RheumNow #ACRBest https://t.co/z0oy9FvheY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Sjogren's in a Plenary! Remibrutinib (BTKi) in SjS Improved ESSDAI at wk 24, but NONE on ESSPRI (more patient-centric ie fatigue, dryness, joint pain) Definitely helps w/lab abnormalities, but worried benefit for outcomes that matter may be limited #ACR22 @RheumNow abstr#1113 https://t.co/GutY8KndbR
Mike Putman EBRheum ( View Tweet)
Post hoc analysis of 3 PsA/SPA trials: no effect of tobacco 🚬 on TOFA efficacy But numerically higher TEAEs Contrasting w/ data from real world TNF Interesting data but small sample size & events N https://t.co/gv8uvcThMD Abs#1036 #ACR22 @Rheumnow https://t.co/HCJT0XF1tg

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Interesting Abs 0825: MAS was most often caused 2nd to a benign disease. Most common presentation: fever w/ cytopenias. Ferritin levels more than 7511 and ferritin/ CRP levels more than 204.5 ass'd w/ higher mortality. #ACR22 @RheumNow https://t.co/HEuMedE9Rh https://t.co/6f4bf7x9Hh

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Initial Remibrutinib (oral, covalent, and highly specific inhibitor of Bruton’s tyrosine kinase (BTK)) data in SS shows good efficacy and safety. Plenary Abs 1113 #ACR22 @RheumNow https://t.co/5Zr0Y1ueAv https://t.co/Iy194YUWNC

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
RheumNow’s expanded coverage of the #ACR22 annual meeting is sponsored in part by Novartis. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

DANBIO registry: 1600+ pts RA, AxSpA, PsA Infiximab biosimilar to biosimilar switch (CT-P13 -> GP1111) Maintenance at 1yr: >80% > withdrawal in original IFX naive, but higher BL DA Do second time switchers do better because of past switch experience? Abs#1112 #ACR22 @RheumNow https://t.co/IgjhGLVESz
Aurelie Najm AurelieRheumo ( View Tweet)
2nd Plenary Session! Remibrutinib (BTK inhibitor) for treatment of Sjögren's syndrome (phase 2 study) Improvement of ESSDAI, salivary flow and pathologically elevated Ig's Abs#1113 @RheumNow #ACR22 https://t.co/vdgxBPe6qd
Robert B Chao, MD doctorRBC ( View Tweet)
We're used to originator-to-biosimilar switches. Widespread biosim use means we now see biosim-biosim switches (incl as second switch) DANBIO data retention good I see the hallmarks of nocebo still an issue I think we can all agree: ongoing education important #ACR22 @RheumNow https://t.co/6PcMfEEozk
David Liew drdavidliew ( View Tweet)
Yes. But this only accounts for 1/3 of risk to develop clinical RA. We need a better understanding of the other 2/3 so we can propose efficient preventive interventions. #ACR22 @RheumNow https://t.co/RRzlAISFK3

Links:

Aurelie Najm AurelieRheumo ( View Tweet)

@EBRheum @RheumNow Its more than that…tubulointerstitial kidney disease, lymph nodes, salivary gland, and hepatobiliary tract disease don’t show findings of vasculitis. Certain HLA haplotypes more linked with autoimmune diseases are present. #ACR @RheumNow

Fabio Torres FabioTorressav ( View Tweet)

@AlexisOgdie et al: PsA pts who were MDA, DAPSA LDA, or ACR50 responders vs non-responders reported clinically meaningful improvements across PROs including pain, physical function, fatigue, and work productivity. Abs 1019 #ACR22 @RheumNow https://t.co/MK13sXS3Or https://t.co/TfCrQMV2JX

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Presence of DFS pattern should not be used to indiscriminately exclude presence of a rheumatic disease based on retrospective study in Abs 0814. RA, SS and Raynaud's ICD10 codes were higher among DFS pattern ANA per chart review. #ACR22 @RheumNow https://t.co/mLtppvR4dk https://t.co/6Lukxntqe7

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Biosimilar to biosimilar effective in treatment of RA/PsA/AxSpA. Large study looking at infliximab biosimilar switching - resulted in high retention rates and virtually no change in disease activity. @RheumNow #ACR22 Abs#1112 https://t.co/uNRXLewo4M
Robert B Chao, MD doctorRBC ( View Tweet)
The greater the PsAID score, the more likely escalation in PsA treatment. Noted significant correlation between PsAID and physician global scores. Do you use PsAID in your clinic? Abs 1028 #ACR22 @RheumNow https://t.co/gcjm2XgPE3 https://t.co/bKPtXz5Nw8

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Abstr #1494 determinants of clinically important worsening (CIW) of early axSpA - CIW = ASDAS ↑ > 0.9 b/w 2 visits - Tender Joint count and ASAS-NSAID score associated w/ CIW - MRI SI Jt inflammation & structural damage predictive of CIW @RheumNow #ACR22 https://t.co/Dgeh25BaWM
Akhil Sood MD AkhilSoodMD ( View Tweet)
Global survey of rheumatic irAE people (me included) Standard case Variable answers, broadly distributed none are wrong We'll move from expert extrapolation of concepts to data-driven answers, with the right foundations👍 ABST0776 @MDAndersonNews @msalmazor #ACR22 @RheumNow https://t.co/5gMzWuCXd7
David Liew drdavidliew ( View Tweet)
Do patients with PsA like online wellness programs? #ACR22 @RheumNow 🌈 186 patients, 86% women, 90% White 🌈sleep and nutrition were highly rated for wellness 🌈cost and fatigue barriers to adopting wellness behaviors 🌈 27% were open to an online wellness program

Catherine Sims, MD DrCassySims ( View Tweet)

BASDAI and ASDAS performed similarly in axPsA pts, both demonstrating weak correlations w/ peripheral arthritis and moderate/strong correlations w/ pt fatigue and pain. Abs 1037 #ACR22 @RheumNow https://t.co/WRQx1hkIll https://t.co/kJVIWyVv2w

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
3 yr interim RELIANCE study analysis shows long-term CAN tx is safe and effective in CAPS regardless of the underlying mutation and TRAPS. Abs 0812 #ACR22 @RheumNow https://t.co/pgSq1IICJK and https://t.co/Y2NUpgXGPL https://t.co/j9DMFF7V8S

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
×